GRI Bio Inc

GRI Bio Inc a clinicalstage biopharmaceutical company focuses on discovering developing and commercializing therapies that target diseases leading to inflammatory fibrotic and autoimmune disorders in the United States Its lead product candidate is GRI0621 an oral inhibitor of type 1 Natural Killer T cells which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis The companys portfolio also includes GRI0803 a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders a proprietary library of 500 compounds and GRI0124 and GRI0729 for balance inflammatory immune responses The company was formerly known as Glycoregimmune Inc GRI Bio Inc was founded in 2009 and is based in LA Jolla California